drugset
drugset / Trial / NCT04905043

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

NCT04905043 ↗

Phase 1 Completed 12 enrolled Acerta Pharma BV
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effect of gastric pH on acalabrutinib pharmacokinetics in healthy participants.

Timeline

Start
2016-06-03
Primary completion
2016-07-11
Completion
2016-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral

Indications

No indication recorded.